Description

Oportuzumab Monatox is a targeted immunotoxin designed for precision therapeutic applications. This compound is critical for advanced research and development in targeted cancer therapies, offering a mechanism to deliver cytotoxic agents directly to specific cell populations. It is primarily utilized by pharmaceutical R&D teams, biotech companies, and academic research institutions focused on oncology and immunology. Its development represents a significant step in the creation of next-generation antibody-drug conjugates (ADCs) and similar targeted treatment modalities.

Application

• Targeted Cancer Therapy Research: Primary application in the preclinical and clinical development of novel oncology treatments.
• Antibody-Drug Conjugate (ADC) Development: Serves as a key payload or model compound for constructing and testing new ADC candidates.
• Immunotoxin Studies: Used in research to understand the efficacy and mechanism of action of engineered toxins fused to targeting antibodies.
• Cell-Specific Cytotoxicity Assays: Employed in vitro and in vivo to evaluate targeted cell-killing and therapeutic windows.
• Biomarker and Target Validation: A tool for validating the expression and therapeutic relevance of specific cell surface antigens.
• Pharmacology and Toxicology Profiling: Essential for studying the pharmacokinetics, biodistribution, and safety profile of targeted therapeutics.

Basic Information

Product Name	Oportuzumab Monatox
CAS No.	945228-48-8
Molecular Formula	Contact for details
Molecular Weight	Contact for details
Synonyms	Oportuzumab monatox; Immunotoxin oportuzumab monatox; Anti-EPCAM recombinant immunotoxin; VB4-845; Cantuzumab mertansine analog; Targeted cytotoxic fusion protein; Monoclonal antibody-targeted toxin
EINECS	Contact for details

Quality Control

Our Oportuzumab Monatox is manufactured under stringent quality systems suitable for research and development purposes. Each batch is subjected to a comprehensive suite of analytical tests, including identity confirmation, purity assessment, and biological activity assays, to ensure consistency and reliability. Certificates of Analysis (COA) detailing specific results for purity, endotoxin levels, and sterility (where applicable) are provided to support your critical research and regulatory documentation needs.

Storage

Preserve in a tightly closed container, protected from light. Store at -20°C or below for long-term stability. This product is hygroscopic (moisture-sensitive) and should be handled under controlled, dry conditions to prevent degradation. Allow the vial to equilibrate to room temperature before opening to minimize moisture condensation.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder
Identification (HPLC/MS)	Conforms to reference standard
Purity (HPLC)	≥ 95.0%
Protein Content	≥ 90% of dry weight
Biological Activity (Cell-based assay)	Reported per batch
Endotoxin	< 10 EU/mg
Moisture Content (KF)	< 5.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.